Mar 5, 2020 7:00 am EST Castle Biosciences Announces Issuance of First U.S. Patent Covering DecisionDx-Melanoma
Feb 25, 2020 7:00 am EST Castle Biosciences to Release Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 10, 2020
Feb 12, 2020 7:00 am EST Castle Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Jan 20, 2020 7:00 am EST Castle Biosciences Announces Study Establishing the Value of Integrating DecisionDx-SCC Test into Management of High-Risk Cutaneous Squamous Cell Carcinoma
Jan 9, 2020 5:00 pm EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019
Dec 30, 2019 7:00 am EST Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology
Dec 3, 2019 5:00 pm EST Castle Biosciences Announces Time Change for Presentation at the Evercore ISI Second Annual HealthCONx
Nov 25, 2019 7:00 am EST Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations
